Plan I drugs are by far the most difficult to get authorization to exploration having said that, clinical trials are accepted and so are ongoing from the US.2000 (Investigation) : Regulatory approval to resume psychedelics exploration A gaggle of Johns Hopkins researchers was the primary to get regulatory acceptance in The us to resume study with p